Tethering Innate Surface Receptors on Dendritic Cells: A New Avenue for Immune Tolerance Induction?

DC subsets Fc receptors antibody format dendritic cells immune tolerance pathogen recognition receptors therapeutic antibodies

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
24 Jul 2020
Historique:
received: 08 07 2020
revised: 22 07 2020
accepted: 23 07 2020
entrez: 30 7 2020
pubmed: 30 7 2020
medline: 18 2 2021
Statut: epublish

Résumé

Dendritic cells (DCs) play a key role in immunity and are highly potent at presenting antigens and orienting the immune response. Depending on the environmental signals, DCs could turn the immune response toward immunity or immune tolerance. Several subsets of DCs have been described, with each expressing various surface receptors and all participating in DC-associated immune functions according to their specific skills. DC subsets could also contribute to the vicious circle of inflammation in immune diseases and establishment of immune tolerance in cancer. They appear to be appropriate targets in the control of inflammatory diseases or regulation of autoimmune responses. For all these reasons, in situ DC targeting with therapeutic antibodies seems to be a suitable way of modulating the entire immune system. At present, the field of antibody-based therapies has mainly been developed in oncology, but it is undergoing remarkable expansion thanks to a wide variety of antibody formats and their related functions. Moreover, current knowledge of DC biology may open new avenues for targeting and modulating the different DC subsets. Based on an update of pathogen recognition receptor expression profiles in human DC subsets, this review evaluates the possibility of inducing tolerant DCs using antibody-based therapeutic agents.

Identifiants

pubmed: 32722168
pii: ijms21155259
doi: 10.3390/ijms21155259
pmc: PMC7432195
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : French Ministere of Research
ID : ANR-10-LABX53-01

Références

Immunol Rev. 2015 Nov;268(1):25-51
pubmed: 26497511
Mol Immunol. 2015 Oct;67(2 Pt A):95-106
pubmed: 25637431
Diabetes. 2008 Sep;57(9):2341-7
pubmed: 18559659
J Leukoc Biol. 2009 Mar;85(3):518-25
pubmed: 19028959
Annu Rev Immunol. 2004;22:33-54
pubmed: 15032573
Int Rev Immunol. 2017 Mar 4;36(2):57-73
pubmed: 28060562
Life Sci. 2020 Aug 1;254:117580
pubmed: 32205087
J Immunol. 2008 Mar 15;180(6):3647-50
pubmed: 18322168
BMJ Open. 2019 Sep 9;9(9):e030309
pubmed: 31501122
Vaccines (Basel). 2016 Mar 28;4(2):
pubmed: 27043640
Int Rev Immunol. 2014 Nov-Dec;33(6):443-53
pubmed: 24911430
J Allergy Clin Immunol. 2018 Oct;142(4):1185-1193.e4
pubmed: 29890236
J Immunol. 2012 Jun 1;188(11):5644-54
pubmed: 22547696
Curr Opin Cell Biol. 2003 Oct;15(5):539-46
pubmed: 14519388
Protein Eng Des Sel. 2018 Jul 1;31(7-8):249-256
pubmed: 29718394
Immunity. 2007 Apr;26(4):519-31
pubmed: 17412618
Annu Rev Immunol. 2012;30:491-529
pubmed: 22224766
BioDrugs. 2013 Feb;27(1):35-53
pubmed: 23329400
Annu Rev Immunol. 2003;21:685-711
pubmed: 12615891
Blood. 2008 Apr 15;111(8):4245-53
pubmed: 18258799
J Immunol. 2012 Jul 1;189(1):92-101
pubmed: 22649202
J Clin Invest. 2006 Apr;116(4):916-28
pubmed: 16543948
Transplantation. 2008 Feb 15;85(3):369-77
pubmed: 18301333
Nat Rev Rheumatol. 2016 Dec;12(12):703-715
pubmed: 27652503
Front Immunol. 2012 Apr 18;3:79
pubmed: 22566960
PLoS One. 2018 May 8;13(5):e0196994
pubmed: 29738575
J Immunol. 2008 Nov 15;181(10):6923-33
pubmed: 18981112
Clin Exp Immunol. 2018 Jan;191(1):107-115
pubmed: 28898406
Eur J Immunol. 2009 May;39(5):1379-86
pubmed: 19291703
J Evid Based Med. 2013 Nov;6(4):250-64
pubmed: 24325419
Mol Med. 2018 May 3;24(1):17
pubmed: 30134798
Methods. 2019 Feb 1;154:3-9
pubmed: 30172007
Joint Bone Spine. 2018 Jan;85(1):47-52
pubmed: 28461199
EMBO Mol Med. 2015 Mar 11;7(4):464-76
pubmed: 25762615
Nat Rev Immunol. 2014 Feb;14(2):94-108
pubmed: 24445665
Protein Eng Des Sel. 2017 Sep 1;30(9):673-684
pubmed: 28981915
MAbs. 2020 Jan-Dec;12(1):1703531
pubmed: 31847708
Transpl Int. 2008 May;21(5):483-94
pubmed: 18266776
Future Microbiol. 2009 Sep;4(7):879-90
pubmed: 19722841
Blood. 2013 May 2;121(18):3609-18
pubmed: 23460612
Nat Commun. 2018 Feb 28;9(1):877
pubmed: 29491415
Immunol Cell Biol. 2010 Oct;88(7):716-26
pubmed: 20212510
Front Immunol. 2017 Apr 07;8:394
pubmed: 28439271
J Exp Med. 2000 Feb 7;191(3):411-6
pubmed: 10662786
Curr Opin Hematol. 2016 Jan;23(1):28-35
pubmed: 26554892
Ann Rheum Dis. 2017 Jan;76(1):227-234
pubmed: 27117700
Adv Exp Med Biol. 1997;417:1-6
pubmed: 9286329
Curr Top Microbiol Immunol. 2017;410:47-71
pubmed: 28900681
Semin Immunopathol. 2015 Mar;37(2):97-106
pubmed: 25420452
J Immunol. 2003 Sep 15;171(6):3296-302
pubmed: 12960360
Transplantation. 2018 Jan;102(1):59-69
pubmed: 28777210
Int Rev Cell Mol Biol. 2019;348:1-68
pubmed: 31810551
Cytotherapy. 2012 May;14(5):598-607
pubmed: 22424215
Rheumatol Int. 2017 Jul;37(7):1043-1051
pubmed: 28236220
Curr Opin Pharmacol. 2019 Aug;47:110-118
pubmed: 30986625
J Immunol. 2017 Feb 15;198(4):1403-1414
pubmed: 28167651
Drug Discov Today. 2015 Jul;20(7):838-47
pubmed: 25728220
J Clin Immunol. 2015 Jan;35(1):1-10
pubmed: 25312698
Cytokine. 2015 Aug;74(2):181-9
pubmed: 25846205
Front Immunol. 2014 Apr 01;5:131
pubmed: 24744755
Front Immunol. 2017 Oct 27;8:1424
pubmed: 29163499
Pathol Biol (Paris). 2003 Mar;51(2):59-60
pubmed: 12801800
Autoimmun Rev. 2019 Feb;18(2):123-128
pubmed: 30572136
Inflamm Allergy Drug Targets. 2009 Mar;8(1):80-6
pubmed: 19275696
Transplant Res. 2012 Sep 28;1(1):11
pubmed: 23369457
Trends Immunol. 2013 Sep;34(9):440-5
pubmed: 23831267
J Exp Med. 2003 May 5;197(9):1107-17
pubmed: 12719479
Yonsei Med J. 2018 Sep;59(7):807-815
pubmed: 30091313
Immunobiology. 2015 Feb;220(2):193-9
pubmed: 25108563
Clin Immunol. 2012 Mar;142(3):332-42
pubmed: 22225835
J Crohns Colitis. 2015 Dec;9(12):1071-8
pubmed: 26303633
Science. 2017 Oct 6;358(6359):85-90
pubmed: 28931639
J Immunol Res. 2017;2017:7573154
pubmed: 28702462
Immunology. 2018 May;154(1):3-20
pubmed: 29313948
Front Immunol. 2014 Aug 27;5:408
pubmed: 25221553
Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9927-32
pubmed: 21628593
Semin Immunol. 2018 Feb;35:3-11
pubmed: 29242034
J Exp Med. 2002 Dec 16;196(12):1627-38
pubmed: 12486105
Nat Rev Immunol. 2018 Jun;18(6):374-389
pubmed: 29581532
Nat Immunol. 2012 Sep;13(9):817-22
pubmed: 22910394

Auteurs

Lucille Lamendour (L)

GICC EA 7501, Université de Tours, UFR de Médecine, 10 Boulevard Tonnellé, F-37032 Tours, France.

Nora Deluce-Kakwata-Nkor (N)

GICC EA 7501, Université de Tours, UFR de Médecine, 10 Boulevard Tonnellé, F-37032 Tours, France.

Caroline Mouline (C)

GICC EA 7501, Université de Tours, UFR de Médecine, 10 Boulevard Tonnellé, F-37032 Tours, France.

Valérie Gouilleux-Gruart (V)

GICC EA 7501, Université de Tours, UFR de Médecine, 10 Boulevard Tonnellé, F-37032 Tours, France.

Florence Velge-Roussel (F)

GICC EA 7501, Université de Tours, UFR de Médecine, 10 Boulevard Tonnellé, F-37032 Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH